We are Benzenesulfonyl Chloride CAS:98-09-9 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
CAS No: 98-09-9
Product Name: Benzenesulfonyl Chloride
Density: 1.4±0.1 g/cm3
Boiling Point: 251.5±9.0 °C at 760 mmHg
Melting Point: 14.5 °C
Molecular Formula: C6H5ClO2S
Molecular Weight: 176.621
Flash Point: 105.9±18.7 °C
Exact Mass: 175.969879
Vapour Pressure: 0.0±0.5 mmHg at 25°C
Index of Refraction: 1.554
Stability: Stable. Incompatible with water, strong oxidizing agents, strong bases, methyl formamide, dimethyl sulfoxide.
Water Solubility: may decompose
Appearance: Colorless to light yellow transparent liquid
Free acid by HCl: ≤0.1%
Insoluble impurity in alkali: ≤0.1%
Intermediates of Bensultap CAS: 17606-31-4.
Pesticides, dyes, pharmaceutical intermediates. Applicationd for the manufacture of ice dye bases, such as red base B and red base GL Applicationd in the manufacture of sulfa drugs. Phenylsulfonyl chloride is a reagent for the determination of gels.
Phenylsulfonyl chloride is an organic synthetic raw material. It is used in the synthesis of sodium thiobenzenesulfonate, an intermediate for pesticides and insecticides of insect pests.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.16419-60-6 With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.2-fluoro-3-metilpiridina CAS:2369-18-8 With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.Chloral hydrate CAS:302-17-0 With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.”This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.